IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
received:
09
01
2020
accepted:
24
05
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren's syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.
Identifiants
pubmed: 32620913
doi: 10.1038/s41598-020-66981-z
pii: 10.1038/s41598-020-66981-z
pmc: PMC7335044
doi:
Substances chimiques
Autoantibodies
0
Immunoglobulin M
0
Phosphorylcholine
107-73-3
Malondialdehyde
4Y8F71G49Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11010Investigateurs
Lorenzo Beretta
(L)
Barbara Vigone
(B)
Jacques-Olivier Pers
(JO)
Alain Saraux
(A)
Valérie Devauchelle-Pensec
(V)
Divi Cornec
(D)
Sandrine Jousse-Joulin
(S)
Bernard Lauwerys
(B)
Julie Ducreux
(J)
Anne-Lise Maudoux
(AL)
Carlos Vasconcelos
(C)
Ana Tavares
(A)
Esmeralda Neves
(E)
Raquel Faria
(R)
Mariana Brandão
(M)
Ana Campar
(A)
António Marinho
(A)
Fátima Farinha
(F)
Isabel Almeida
(I)
Miguel Angel Gonzalez-Gay Mantecón
(MAG)
Ricardo Blanco Alonso
(RB)
Alfonso Corrales Martínez
(AC)
Ricard Cervera
(R)
Ignasi Rodríguez-Pintó
(I)
Gerard Espinosa
(G)
Rik Lories
(R)
Ellen De Langhe
(E)
Nicolas Hunzelmann
(N)
Doreen Belz
(D)
Torsten Witte
(T)
Niklas Baerlecken
(N)
Georg Stummvoll
(G)
Michael Zauner
(M)
Michaela Lehner
(M)
Eduardo Collantes
(E)
Rafaela Ortega-Castro
(R)
Mª Angeles Aguirre-Zamorano
(MA)
Alejandro Escudero-Contreras
(A)
Mª Carmen Castro-Villegas
(MC)
Norberto Ortego
(N)
María Concepción Fernández Roldán
(MCF)
Enrique Raya
(E)
Inmaculada Jiménez Moleón
(IJ)
Enrique de Ramon
(E)
Isabel Díaz Quintero
(ID)
Pier Luigi Meroni
(PL)
Maria Gerosa
(M)
Tommaso Schioppo
(T)
Carolina Artusi
(C)
Carlo Chizzolini
(C)
Aleksandra Zuber
(A)
Donatienne Wynar
(D)
Laszló Kovács
(L)
Attila Balog
(A)
Magdolna Deák
(M)
Márta Bocskai
(M)
Sonja Dulic
(S)
Gabriella Kádár
(G)
Falk Hiepe
(F)
Velia Gerl
(V)
Silvia Thiel
(S)
Manuel Rodriguez Maresca
(MR)
Antonio López-Berrio
(A)
Rocío Aguilar-Quesada
(R)
Héctor Navarro-Linares
(H)
Références
Gabriel, S. E. & Michaud, K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11, 229, https://doi.org/10.1186/ar2669 (2009).
doi: 10.1186/ar2669
pubmed: 19519924
pmcid: 2714099
Shapira, Y., Agmon-Levin, N. & Shoenfeld, Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6, 468–476, https://doi.org/10.1038/nrrheum.2010.86 (2010).
doi: 10.1038/nrrheum.2010.86
pubmed: 20567251
Cooper, G. S., Bynum, M. L. & Somers, E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33, 197–207, https://doi.org/10.1016/j.jaut.2009.09.008 (2009).
doi: 10.1016/j.jaut.2009.09.008
pubmed: 19819109
pmcid: 2783422
Aranow, C. & Ginzler, E. M. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9, 166–169, https://doi.org/10.1191/096120300678828208 (2000).
doi: 10.1191/096120300678828208
pubmed: 10805482
Frostegard, J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25, 1776–1785 (2005).
doi: 10.1161/01.ATV.0000174800.78362.ec
Svenungsson, E. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887–1893 (2001).
doi: 10.1161/hc4101.097518
Shoenfeld, Y. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337–3347 (2005).
doi: 10.1161/CIRCULATIONAHA.104.507996
Miller, Y. I. et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 108, 235–248, https://doi.org/10.1161/CIRCRESAHA.110.223875 (2011).
doi: 10.1161/CIRCRESAHA.110.223875
pubmed: 21252151
pmcid: 3075542
Al-Riyami, L. & Harnett, W. Immunomodulatory properties of ES-62, a phosphorylcholine-containing glycoprotein secreted by Acanthocheilonema viteae. Endocrine, metabolic & immune disorders drug targets 12, 45–52 (2012).
doi: 10.2174/187153012799278893
Harnett, W. & Harnett, M. M. Phosphorylcholine: friend or foe of the immune system? Immunol Today 20, 125–129 (1999).
doi: 10.1016/S0167-5699(98)01419-4
Papac-Milicevic, N., Busch, C. J. & Binder, C. J. Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis. Adv Immunol 131, 1–59, https://doi.org/10.1016/bs.ai.2016.02.001 (2016).
doi: 10.1016/bs.ai.2016.02.001
pubmed: 27235680
pmcid: 5892703
Frostegard, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 11, 117, https://doi.org/10.1186/1741-7015-11-117 (2013).
doi: 10.1186/1741-7015-11-117
pubmed: 23635324
pmcid: 3658954
Caidahl, K. et al. IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes. Int J Cardiol 167, 464–469, S0167-5273(12)00036-8, https://doi.org/10.1016/j.ijcard.2012.01.018 (2013).
Su, J. et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188, 160–166 (2006).
doi: 10.1016/j.atherosclerosis.2005.10.017
Thiagarajan, D. et al. Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60-Year-Olds. Journal of the American Heart Association 5, https://doi.org/10.1161/JAHA.116.004415 (2016).
Anania, C. et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 12, R214, https://doi.org/10.1186/ar3193 (2010).
doi: 10.1186/ar3193
pubmed: 21092251
pmcid: 3046524
Su, J. et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology 47, 1144–1150, https://doi.org/10.1093/rheumatology/ken120 (2008).
doi: 10.1093/rheumatology/ken120
pubmed: 18522961
Ajeganova, S., Fiskesund, R., de Faire, U., Hafstrom, I. & Frostegard, J. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study. Clin Exp Rheumatol 29, 942–950, 4758 (2011).
Vas, J., Gronwall, C., Marshak-Rothstein, A. & Silverman, G. J. Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum 64, 3388–3398, https://doi.org/10.1002/art.34537 (2012).
doi: 10.1002/art.34537
pubmed: 22577035
pmcid: 3462267
Sobel, M. et al. Low levels of a natural IgM antibody are associated with vein graft stenosis and failure. J Vasc Surg 58, 997–1005 e1001-1002, S0741-5214(13)00864-1, https://doi.org/10.1016/j.jvs.2013.04.042 (2013).
Gleissner, C. A. et al. Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clinical research in cardiology: official journal of the German Cardiac Society 104, 13–22, https://doi.org/10.1007/s00392-014-0750-y (2015).
doi: 10.1007/s00392-014-0750-y
Wilde, B. et al. Phosphorylcholine antibodies are diminished in ANCA-associated vasculitis. Eur J Clin Invest 45, 686–691, https://doi.org/10.1111/eci.12457 (2015).
doi: 10.1111/eci.12457
pubmed: 25940757
Imhof, A. et al. Long-term prognostic value of IgM antibodies against phosphorylcholine for adverse cardiovascular events in patients with stable coronary heart disease. Atherosclerosis 243, 414–420, https://doi.org/10.1016/j.atherosclerosis.2015.10.024 (2015).
doi: 10.1016/j.atherosclerosis.2015.10.024
pubmed: 26520895
Nguyen, T. G. et al. Aberrant levels of natural IgM antibodies in osteoarthritis and rheumatoid arthritis patients in comparison to healthy controls. Immunol Lett 170, 27–36, https://doi.org/10.1016/j.imlet.2015.12.009 (2016).
doi: 10.1016/j.imlet.2015.12.009
pubmed: 26744098
Lopez, P. et al. IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile. Rheumatology (Oxford), https://doi.org/10.1093/rheumatology/kez264 (2019).
Rahman, M. et al. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. Clinical immunology 166–167, 27–37, https://doi.org/10.1016/j.clim.2016.04.007 (2016).
doi: 10.1016/j.clim.2016.04.007
pubmed: 27102765
Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R. & Alarcon-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol 14, 75–93, https://doi.org/10.1038/nrrheum.2017.220 (2018).
doi: 10.1038/nrrheum.2017.220
pubmed: 29362467
Sun, J. et al. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. Atherosclerosis 268, 36–48, https://doi.org/10.1016/j.atherosclerosis.2017.11.010 (2018).
doi: 10.1016/j.atherosclerosis.2017.11.010
pubmed: 29175653
Lundstrom, S. L., Zhang, B., Rutishauser, D., Aarsland, D. & Zubarev, R. A. SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics. Sci Rep 7, 41929, https://doi.org/10.1038/srep41929 (2017).
doi: 10.1038/srep41929
pubmed: 28167817
pmcid: 5294601
Benjamin, C. et al. Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open 4, e000783, https://doi.org/10.1136/rmdopen-2018-000783 (2018).
doi: 10.1136/rmdopen-2018-000783
Ciang, N. C., Pereira, N. & Isenberg, D. A. Mixed connective tissue disease-enigma variations? Rheumatology (Oxford) 56, 326–333, https://doi.org/10.1093/rheumatology/kew265 (2017).
doi: 10.1093/rheumatology/kew265
Triantafyllias, K. et al. High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity. Clin Exp Rheumatol (2019).
Frostegard, J. et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52, 192–200 (2005).
doi: 10.1002/art.20780
Lopes-Virella, M. F. et al. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 224, 526–531, https://doi.org/10.1016/j.atherosclerosis.2012.08.006 (2012).
doi: 10.1016/j.atherosclerosis.2012.08.006
pubmed: 22963984
pmcid: 4240617
Fiskesund, R. et al. Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J Immunol 192, 4551–4559, https://doi.org/10.4049/jimmunol.1303035 (2014).
doi: 10.4049/jimmunol.1303035
pubmed: 24729615
de Faire, U. et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 34, 73–79, S0896-8411(09)00068-7, https://doi.org/10.1016/j.jaut.2009.05.003 (2010).
Fiskesund, R. et al. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol 2, 13–18, https://doi.org/10.1016/j.rinim.2012.01.001 , S2211-2839(12)00002-0 (2012).
Chen, Y., Park, Y. B., Patel, E. & Silverman, G. J. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol 182, 6031–6043, https://doi.org/10.4049/jimmunol.0804191 (2009).
doi: 10.4049/jimmunol.0804191
pubmed: 19414754
pmcid: 4428684
Nagata, S., Hanayama, R. & Kawane, K. Autoimmunity and the clearance of dead cells. Cell 140, 619–630, https://doi.org/10.1016/j.cell.2010.02.014 (2010).
doi: 10.1016/j.cell.2010.02.014
pubmed: 20211132
Miyara, M. et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175, 8392–8400 (2005).
doi: 10.4049/jimmunol.175.12.8392
Barath, S. et al. Regulatory T cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 35, 300–304, https://doi.org/10.1080/03009740600709790 (2006).
doi: 10.1080/03009740600709790
pubmed: 16882595
Alunno, A. et al. T Regulatory and T Helper 17 Cells in Primary Sjogren’s Syndrome: Facts and Perspectives. Mediators of inflammation 2015, 243723, https://doi.org/10.1155/2015/243723 (2015).
doi: 10.1155/2015/243723
pubmed: 26060357
pmcid: 4427804
Frantz, C., Auffray, C., Avouac, J. & Allanore, Y. Regulatory T Cells in Systemic Sclerosis. Front Immunol 9, 2356, https://doi.org/10.3389/fimmu.2018.02356 (2018).
doi: 10.3389/fimmu.2018.02356
pubmed: 30374354
pmcid: 6196252
Shaw, P. X. et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21, 1333–1339 (2001).
doi: 10.1161/hq0801.093587
Fogelman, A. M. et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 77, 2214–2218 (1980).
doi: 10.1073/pnas.77.4.2214
Duryee, M. J. et al. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free Radic Biol Med 49, 1480–1486, https://doi.org/10.1016/j.freeradbiomed.2010.08.001 (2010).
doi: 10.1016/j.freeradbiomed.2010.08.001
pubmed: 20696236
pmcid: 2952714
Frostegard, J. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33–43 (1999).
doi: 10.1016/S0021-9150(99)00011-8
Frostegard, J., Tao, W., Rastam, L., Lindblad, U. & Lindeberg, S. Antibodies against Phosphorylcholine among New Guineans Compared to Swedes: An Aspect of the Hygiene/Missing Old Friends Hypothesis. Immunol Invest 46, 59–69, https://doi.org/10.1080/08820139.2016.1213279 (2017).
doi: 10.1080/08820139.2016.1213279
pubmed: 27611006
Frostegård, J. et al. Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond) 4, 7 (2007).
doi: 10.1186/1743-7075-4-7
Agmon-Levin, N. et al. Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. Ann N Y Acad Sci 1173, 675–682, NYAS4671, https://doi.org/10.1111/j.1749-6632.2009.04671.x (2009).